Quanterix Corporation Q3 2025 Earnings Recap

QTRX Q3 2025 November 11, 2025

Quanterix Corporation reported a solid Q3 2025 performance with $40.2 million in revenue, marking a 12% year-over-year increase and demonstrating effective integration post-Akoya acquisition.

Earnings Per Share Miss

$-0.36 vs $-0.23 est.

-56.5% surprise

Revenue Beat

40150000 vs 37951670 est.

+5.8% surprise

Market Reaction

1-Day -2.34%

5-Day +12.11%

30-Day +49.02%

Key Takeaways

Achieved $67 million of the targeted $85 million in cost synergies from the Akoya acquisition within just over three months.
Instrumentation and accelerator revenues showed sequential growth, signaling potential market stabilization.
Invested approximately $27 million in R&D, underlining commitment to innovation, particularly in Alzheimer's diagnostics.
On track to maintain a strong cash position with projected year-end cash of around $120 million and no debt.
Early success in commercial synergy with growing interest in multimodal biomarker strategies among customers.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit QTRX on AllInvestView.